N. Anthony Coles, MD is Chief Executive Officer of Cerevel Therapeutics. Previously, Coles co-founded and was the Chairperson and Chief Executive Officer of Yumanity Therapeutics, LLC, a clinical-stage biopharmaceutical company specializing in Alzheimer’s and Parkinson’s diseases. Prior to Yumanity Therapeutics, Coles was Chairperson and CEO of TRATE Enterprises, LLC.
Previously, Coles was Chair and CEO of Onyx Pharmaceuticals, Inc. Prior to Onyx, he was President, Chief Executive Officer and a Member of the Board of Directors of NPS Pharmaceuticals, Inc.
Coles was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Inc. Earlier, Cole held several executive positions at Bristol-Myers Squibb Company and positions of increasing responsibility at Merck & Co., Inc.
Coles earned his Bachelor’s degree at Johns Hopkins University, a Medical degree from Duke University, and a Master’s degree in Public Health from Harvard University.
